Sanofi (SNY.US) suffers another setback in research and development: Rare disease drug Phase III trial halted after failure, new CEO under pressure.

French pharmaceutical giant Sanofi (SNY.US) announced on Wednesday that it will prematurely terminate a study targeting a rare autoimmune disease as an experimental drug failed to demonstrate effectiveness in late-stage clinical trials. This latest setback increases the operational pressure faced by newly appointed CEO Beln Garijo. Key trial termination casts doubt on riliprubart's prospects Sanofi announced it will halt research on riliprubart for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a rare autoimmune disease that causes progressive weakness and sensory impairment in the limbs, severely impacting quality of life. The company stated that it will assess whether to continue with studies for other indications of the drug. Riliprubart was previously considered one of Sanofi's core pipeline drugs in the rare disease field, and was expected by analysts to yield key data this year. This failure undoubtedly disrupts the company's hopes for new products to drive growth. Successive setbacks in research and development pose internal and external challenges for the new CEO Garijo took over in February this year in a time of crisis. Former CEO Paul Hudson was dismissed for not bringing new drugs to market quickly enough. Garijo's primary task is to solidify a new product foundation for Sanofi before its flagship drug Dupixent faces patent cliff and revenue growth momentum gradually diminishes. However, this trial failure is not an isolated incident. Sanofi has faced challenges in several key research and development projects in recent times: - amlitelimab: An experimental drug for the treatment of atopic dermatitis (eczema) with mixed clinical data, failing to demonstrate consistent and reliable therapeutic advantages. - tolebrutinib: An oral BTK inhibitor for multiple sclerosis. Despite receiving marketing authorization in Europe, it has yet to be approved by regulators in the US, casting doubt on its global prospects. Dupixent patent cliff countdown Sanofi's most relied upon growth engine, Dupixent, will soon face the dual impact of biosimilar competition and patent expiration in the coming years. Investors are closely watching whether the company can cultivate enough follow-up products during this critical window period. With the Phase III failure of riliprubart, market confidence in Sanofi's research and development capabilities is likely to be further tested. Analysts point out that new CEO Garijo must quickly revitalize the pipeline, improve clinical success rates, or else the company will struggle to smoothly navigate the performance trough brought by the Dupixent patent cliff.